Cormorant Asset Management is a Boston-based investment manager with investment focus in both public and private market innovative companies in the biotechnology and life sciences marketplace.
Massachusetts, United States
|2017-11-08||Tricida||Series D||$57.5M||Limulus Venture Partners, Longitude Capital, OrbiMed Advisors, Sibling Capital, Venrock, Vivo Capital, and Wellington Management|
|2017-10-13||InflaRx||Series D||$55M||Bain Capital, and RA Capital Management|
|2017-09-26||Autolus||Series C||$80M||Arix Bioscience, Nextech Invest, Syncona Partners, and Woodford Investment Management|
|2017-09-13||BridgeBio Pharma||Series C||$135M||Aisling Capital, American International Group, Janus Capital Group, Kohlberg Kravis Roberts & Co., Perceptive Advisors, and Viking Global Investors|
|2017-09-08||Replimune||Series B||$55M||Atlas Venture, Bain Capital, Forbion Capital Partners, Foresite Capital Management, Leerink Partners, Omega Fund Management, and Redmile Group|